Psychiatry/Psychology | New Developments

National Institute on Drug Abuse

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

CaaMTech Collaborates With National Institutes of Health to Research Psychedelics

Lead Product(s): Psilocybine

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: CaaMTech

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 07, 2020

Details:

The Designer Drug Research Unit at the National Institute on Drug Abuse will conduct research on CaaMTech's library of tryptamine-based compounds.

VistaGen Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19

Lead Product(s): Aloradine

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 28, 2020

Details:

VistaGen plans to submit its proposed protocol for a Phase 2 study of PH94B for treatment of adjustment disorder to the U.S. FDA through the FDA's new Coronavirus Treatment Acceleration Program.

CB Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

CB Therapeutics Enters into Collaboration Agreement with Cleveland Clinic for the Manufacture of Psilocybin

Lead Product(s): Psilocybine

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Cleveland Clinic

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 20, 2020

Details:

The MOU singed between the companies include, production of psilocybin and like molecules used in combination with psychotherapy for the treatment of depression and addiction, and two other molecule.

Adial Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder

Lead Product(s): Ondansetron

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 26, 2020

Details:

AD04 is indicated for people that are positive for select genotypes identified using the Company's propriety companion genetic test.

NineteenGale Therapeutics

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Canada

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

NeuroTheryX Partners with Cyclica to Launch NineteenGale Therapeutics

Lead Product(s): Cannabinoid-based product

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Cyclica

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership March 19, 2020

Details:

Under the initial stealth project, NeuroTheryX combined their phenotype-based drug discovery platform with Cyclica’s first-in-class proteome screening platform.

NYU Grossman School of Medicine

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Antianxiety and Antidepressant Effects from a Single Dose of Psychedelic Drug Persist Years Later in Cancer Patients

Lead Product(s): Psilocybine

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

Psilocybin was associated with enduring antianxiety and antidepressant effects in approximately 60 percent to 80 percent of participants.

Find

Find Novel Psychiatry/Psychology Drugs in Clinical Development

Undisclosed

A collaboration with SCORR Marketing

Product Type

Companies

National Institute on Drug Abuse

CaaMTech Collaborates With National Institutes of Health to Research Psychedelics

VistaGen Therapeutics

VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19

CB Therapeutics

CB Therapeutics Enters into Collaboration Agreement with Cleveland Clinic for the Manufacture of Psilocybin

Adial Pharmaceuticals

Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder

NineteenGale Therapeutics

NeuroTheryX Partners with Cyclica to Launch NineteenGale Therapeutics

NYU Grossman School of Medicine

Antianxiety and Antidepressant Effects from a Single Dose of Psychedelic Drug Persist Years Later in Cancer Patients